Chimeric Therapeutics and OncoBay Clinical Form Partnership to Advance CHM 1101, a Novel CAR T Cell Therapy
- Chimeric and OncoBay Clinical have entered into a strategic partnership to advance and expand the development program for CHM 1101 (CLTX CAR T)
- OncoBay Clinical is a boutique clinical research organization (CRO) that is a subsidiary of the Moffitt Cancer Center and has extensive experience in cell therapy development
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company, is pleased to announce that it has entered a strategic partnership with OncoBay Clinical to provide comprehensive research support to advance and expand the clinical development program for CHM 1101 (CLTX CAR T).
CHM 1101 (CLTX CAR T) is currently being evaluated in a single-site phase 1 clinical trial. This new partnership with OncoBay Clinical will enable the expansion of the program to additional clinical trial sites and aggregate the data from all sites to prepare for the registration phase 2 program. The expansion of this program will take place under Chimeric’s recent IND clearance from the FDA for CHM 1101.
OncoBay Clinical is a first-of-its-kind immuno-oncology CRO specializing in rare and complex oncology indications including cellular therapies. A boutique CRO, OncoBay Clinical is a wholly owned for-profit subsidiary of Moffitt Cancer Center. Through direct partnership, OncoBay Clinical is able to leverage the support of Moffitt’s top scientific advisors, imbedding scientific expertise into every project team and creating “vein-to-vein” control of cell therapy trials.
“OncoBay is a natural partner for us, building upon the cell therapy expertise of our team,” said Jennifer Chow, CEO of Chimeric Therapeutics. “With its experience managing the complexity of cell therapy research programs and scientific support from the Moffitt Cancer Center, we believe that the team at OncoBay is uniquely positioned to support the expansion of the CHM 1101 (CLTX CAR T) development program.”
“We are excited to be partnering with Chimeric on the development of CHM 1101,” said Krystyna Kowalczyk, President and CEO of OncoBay Clinical. “We are confident that our proven ability to succeed in managing the complexities of cell therapy research will enable the accelerated development of Chimeric’s CHM 1101 program.”
Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.
ABOUT CHIMERIC THERAPEUTICS
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.
To bring that promise to life for more patients, Chimeric’s world-class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.
CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy for the treatment of patients with Glioblastoma (GBM). CHM 1101 was developed by scientists at the City of Hope Medical Centre in California where it is currently being studied in a phase 1 clinical trial.
Chimeric also recently announced the expansion of their pipeline with the exclusive licensing of CHM 2101, a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.
Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.
Chief Executive Officer and Managing Director
P: +61 451 896 420